FindTrial
Sign In

Bimagrumab

DRUG9 trials

Sponsors

Novartis Pharmaceuticals, Eli Lilly and Company, Massachusetts General Hospital

Conditions

HealthyMuscle Wasting (Atrophy) After Hip Fracture SurgeryObeseObesityOverweightOverweight or ObesitySarcopeniaSporadic Inclusion Body Myositis

Phase 1

A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
CompletedNCT06890611
Eli Lilly and CompanyHealthy
Start: 2025-03-25End: 2025-09-26Updated: 2025-10-09

Phase 2

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
CompletedNCT02152761
Novartis PharmaceuticalsMuscle Wasting (Atrophy) After Hip Fracture Surgery
Start: 2014-09-16End: 2018-10-25Updated: 2020-08-19
Dose Range Finding Study of Bimagrumab in Sarcopenia
CompletedNCT02333331
Novartis PharmaceuticalsSarcopenia
Start: 2014-12-09End: 2018-06-28Updated: 2021-01-05
A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study
CompletedNCT02468674
Novartis PharmaceuticalsSarcopenia
Start: 2015-07-22End: 2018-12-03Updated: 2020-06-16
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
CompletedNCT05616013
Eli Lilly and CompanyObese, Obesity, Overweight or Obesity
Start: 2022-11-16End: 2025-06-14Updated: 2026-07-08
Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
RecruitingNCT05933499
Massachusetts General HospitalObesity
Start: 2025-11-05End: 2029-03-31Target: 63Updated: 2026-03-27
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Active, not recruitingNCT06643728
Eli Lilly and CompanyObesity, Overweight
Start: 2024-10-21End: 2027-01-01Updated: 2026-05-26
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
WithdrawnNCT06901349
Eli Lilly and CompanyObesity, Overweight
Start: 2025-05-23End: 2025-06-10Updated: 2025-09-24

Phase 3

An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
CompletedNCT02573467
Novartis PharmaceuticalsSporadic Inclusion Body Myositis
Start: 2015-11-02End: 2017-02-13Updated: 2018-03-13

Related Papers

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Nature Medicine2026-03-02
Association of Appendicular Skeletal Muscle Mass Index and Insulin Resistance With Mortality in Multi‐Nationwide Cohorts
Journal of Cachexia Sarcopenia and Muscle2025-04-017 citations
OR10-03 Murine Bimagrumab Co-administration With Incretin Agonists Results In Additive Efficacy And Superior Quality Weight Loss In The Mouse Diet-induced Obesity Model
Journal of the Endocrine Society2023-10-01
370-OR: Optimized Weight Loss with Bimagrumab—Reduced Fat Mass with Increased Muscle Mass by Appetite-Independent Mechanisms
Diabetes2023-06-201 citations
Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial.
2021-05-0124 citations
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
2021-02-1728 citations
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults
JAMA Network Open2020-10-19143 citations
Long-Term Efficacy and Safety of Bimagrumab in Inclusion Body Myositis: 2 Years Results (S38.003)
Neurology2018-04-101 citations